AU2014296212B2 - Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate - Google Patents

Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Download PDF

Info

Publication number
AU2014296212B2
AU2014296212B2 AU2014296212A AU2014296212A AU2014296212B2 AU 2014296212 B2 AU2014296212 B2 AU 2014296212B2 AU 2014296212 A AU2014296212 A AU 2014296212A AU 2014296212 A AU2014296212 A AU 2014296212A AU 2014296212 B2 AU2014296212 B2 AU 2014296212B2
Authority
AU
Australia
Prior art keywords
protein
family
domain
receptor
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014296212A
Other languages
English (en)
Other versions
AU2014296212A1 (en
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of AU2014296212A1 publication Critical patent/AU2014296212A1/en
Application granted granted Critical
Publication of AU2014296212B2 publication Critical patent/AU2014296212B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2014296212A 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Active AU2014296212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
AU2014296212A1 AU2014296212A1 (en) 2016-02-25
AU2014296212B2 true AU2014296212B2 (en) 2020-10-22

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014296212A Active AU2014296212B2 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Country Status (9)

Country Link
US (1) US10378059B2 (https=)
EP (1) EP3027776B1 (https=)
JP (1) JP6913459B2 (https=)
KR (1) KR102389934B1 (https=)
CN (1) CN105531380B (https=)
AU (1) AU2014296212B2 (https=)
CA (1) CA2919690C (https=)
IL (1) IL243894B (https=)
WO (1) WO2015017545A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633566T2 (de) * 1995-07-21 2005-12-08 Savvipharm Inc. Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
JP2010522567A (ja) 2007-03-28 2010-07-08 メダレックス インコーポレーティッド 遺伝子増幅および発現の方法
WO2009120561A2 (en) * 2008-03-22 2009-10-01 Merck & Co., Inc. Methods and gene expression signature for assessing growth factor signaling pathway regulation status
NZ598482A (en) * 2009-09-04 2014-05-30 Tactical Therapeutics Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
WO2012135845A1 (en) * 2011-04-01 2012-10-04 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Mechanism of Action - Tactical Therapeutics", (2013-10-19), URL: http://www.tacticaltherapeutics.com/mechanism-action/, (2017-01-24) *
Geoffrey Shapiro ET AL, "A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer", (2013-06-02), URL: http://www.medsci.cn/webeditor/uploadfile/201306/2013-06-02210743756.pdf, (2017-01-24) *

Also Published As

Publication number Publication date
EP3027776A4 (en) 2017-03-08
CA2919690C (en) 2021-11-02
EP3027776C0 (en) 2024-02-07
JP6913459B2 (ja) 2021-08-04
WO2015017545A1 (en) 2015-02-05
US20150038349A1 (en) 2015-02-05
EP3027776A1 (en) 2016-06-08
KR102389934B1 (ko) 2022-04-21
IL243894B (en) 2020-06-30
US10378059B2 (en) 2019-08-13
JP2016526908A (ja) 2016-09-08
HK1220493A1 (en) 2017-05-05
IL243894A0 (en) 2016-04-21
CN105531380B (zh) 2021-07-13
CA2919690A1 (en) 2015-02-05
EP3027776B1 (en) 2024-02-07
CN105531380A (zh) 2016-04-27
AU2014296212A1 (en) 2016-02-25
KR20160030535A (ko) 2016-03-18

Similar Documents

Publication Publication Date Title
Greco et al. DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy
US11174518B2 (en) Method of classifying and diagnosing cancer
GB2615975A (en) Methods and systems for determining a pregnancy-related state of a subject
Garitano-Trojaola et al. Long non-coding RNAs in haematological malignancies
Lezhnina et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways
Martianov et al. Cell-specific occupancy of an extended repertoire of CREM and CREB binding loci in male germ cells
Zhang et al. Identification of the key transcription factors in esophageal squamous cell carcinoma
Herrer et al. Gene expression network analysis reveals new transcriptional regulators as novel factors in human ischemic cardiomyopathy
Han et al. Dynamic DNA 5-hydroxylmethylcytosine and RNA 5-methycytosine reprogramming during early human development
AU2014296212B2 (en) Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
Jin et al. Relationship between DNA methylation in key region and the differential expressions of genes in human breast tumor tissue
Choi et al. Epigenetic landscape change analysis during human EMT sheds light on a key EMT mediator TRIM29
Akan et al. Severity of coronary artery disease is associated with diminished circANRIL expression: A possible blood based transcriptional biomarker in East Africa
Saleh et al. The long non-coding RNAs (lncRNA) in the pathogenesis of gastric cancer cells: molecular mechanisms and involvement miRNAs
Wu et al. Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis
Nandagopal et al. Long non coding RNA in triple negative breast cancer: a promising biomarker in tumorigenesis
CN110093422A (zh) Linc02159在肺腺癌诊疗中的应用
Prensner et al. Transcriptome sequencing identifies PCAT-1, a novel lincRNA implicated in prostate cancer progression
Sadasivam et al. The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
Brovkina et al. Identification of novel differentially expressing long non-coding RNAs with oncogenic potential
Cserhati et al. Motifome comparison between modern human, Neanderthal and Denisovan
Kumar et al. Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer
Iacobas et al. Papillary thyroid cancer remodels the genetic information processing pathways
Liang et al. Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis
Xu et al. RETRACTED: Identification of potential key genes associated with ovarian clear cell carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)